110 Amendments of Frédérique RIES related to 2023/2075(INI)
Amendment 1 #
Motion for a resolution
Citation 9 a (new)
Citation 9 a (new)
– having regard to Regulation (EU) 2022/123 of the European Parliament and of the Council of 25 January 2022 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices,
Amendment 2 #
Motion for a resolution
Citation 9 b (new)
Citation 9 b (new)
– having regard to Regulation (EU) 2022/2371 of the European Parliament and of the Council of 23 November 2022 on serious cross-border threats to health and repealing Decision No 1082/2013/EU,
Amendment 3 #
Motion for a resolution
Citation 9 c (new)
Citation 9 c (new)
– having regard to Regulation (EU) 2022/370 of the European Parliament and of the Council of 23 November 2022 amending Regulation (EC) No 851/2004 establishing a European centre for disease prevention and control,
Amendment 7 #
Motion for a resolution
Citation 3 a (new)
Citation 3 a (new)
– having regard to to its resolution of 15 January 2020 on the European Green Deal (2019/2956(RSP))and the Commission communication of 11 December 2019 on the European Green Deal (COM(2019)0640),
Amendment 8 #
Motion for a resolution
Citation 4
Citation 4
– having regard to its resolution of 10 July 2020 on the Chemicals Strategy for Sustainability and the Commission communication of 14 October 2020 entitled ‘Chemicals Strategy for Sustainability – Towards a Toxic-Free Environment’ (COM(2020)0667),
Amendment 9 #
Motion for a resolution
Citation 5
Citation 5
– having regard to its resolution of 24 November 2021 on a pharmaceutical strategy for Europe (2021/2013(INI)) and the Commission communication of 25 November 2020 entitled ‘Pharmaceutical Strategy for Europe’ (COM(2020)0761),
Amendment 10 #
Motion for a resolution
Citation 6
Citation 6
– having regard to its resolution of 16 February 2022 on strengthening Europe in the fight against cancer – towards a comprehensive and coordinated strategy and the Commission communication of 3 February 2021 entitled ‘Europe’s Beating Cancer Plan’ (COM(2021)0044),
Amendment 24 #
Motion for a resolution
Citation 9 g (new)
Citation 9 g (new)
– having regard to the Council Recommendation of 13 June 2023 on stepping up EU actions to combat antimicrobial resistance in a One Health approach (AMR),
Amendment 25 #
Motion for a resolution
Citation 4 a (new)
Citation 4 a (new)
– having regard to the Commission communication of 12 May 2021 entitled ‘Pathway to a Healthy Planet for All-EU Action Plan: ‘Towards Zero Pollution for Air, Water and Soil’’ (COM(2021)0400),
Amendment 28 #
Motion for a resolution
Citation 9 d (new)
Citation 9 d (new)
– having regard to the Commission Decision of 16 September 2021 establishing the Health Emergency Preparedness and Response Authority,
Amendment 29 #
Motion for a resolution
Citation 9 e (new)
Citation 9 e (new)
– having regard to the Commission’s proposal for a regulation on the European health data space (COM(2022)0197),
Amendment 30 #
Motion for a resolution
Citation 9 f (new)
Citation 9 f (new)
– having regard to the Commission’s proposal for a Regulation laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency and a Directive on the Union code relating to medicinal products for human use,
Amendment 31 #
Motion for a resolution
Citation 9 h (new)
Citation 9 h (new)
– having regard to the Commission communication of 20 November 2022 entitled ‘EU Global Health Strategy – Better Health for All in a Changing World’ (COM(2022)0675),
Amendment 32 #
Motion for a resolution
Citation 9 i (new)
Citation 9 i (new)
– having regard to the 2030 Agenda for Sustainable Development, in particular Sustainable Development Goal (SDG) 3 target 4, to reduce by one third premature mortality from non- communicable diseases through prevention and treatment and promote mental health and well-being, and SDG 3 target 8, to achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all,
Amendment 33 #
Motion for a resolution
Citation 9 j (new)
Citation 9 j (new)
– having regard to the European Pillar of Social Rights, in particular its principle 16 (healthcare) and 18 (long- term care),
Amendment 56 #
Motion for a resolution
Recital B
Recital B
B. whereas premature deaths as a result of cardiovascular diseases (CVDs), cancers, diabetes and chronic respiratory diseases account for 68 % of all premature deaths in Europe; whereas other NCDs include mental health problems and neurological disorders, liver diseases, kidney diseases, oral diseases, osteoporosis, osteoarthritis and endometriosis among other conditionsallergy and auto-immune diseases, oral diseases, rheumatologic diseases and endometriosis among other conditions; whereas data gaps in specific disease areas can result in a misjudgment of the prevalence of these diseases and their burden;
Amendment 71 #
Ba. whereas the ‘Health in All Policies’ and ‘One Health’ approaches should be promoted further, and efforts to fight non-communicable diseases should be integrated into all EU policies;
Amendment 74 #
Motion for a resolution
Recital C
Recital C
C. whereas NCDs account for the largest share of countries’ healthcare expenditures, costingestimated to cost the EU economies EUR 115 billion, or 0.8 % of GDP annually as well as entailing other societal costs such as loss of productivity and workforce; whereas these costs could be drastically reduced by the implementation of ambitious prevention measures, early and joint detection schemes, and optimal management of the diseases; whereas in 2018, no more than 2.8 % of total health expenditure in the EU was spent on prevention, whereas the costs of treating NCDs remains high5 ; _________________ 5 European Commission, ‘Healthier together – EU non-communicable diseases initiative’, p. 15, June 2022.
Amendment 77 #
Motion for a resolution
Recital C
Recital C
C. whereas NCDs account for the largest share of countries’ healthcare expenditures, costing EU economies and are predicted to lead to the loss of potential productive years among employees impacted by such conditions, resulting in a cost of EUR 115 billion, or 0.8 % of GDP annually as well as entailing other societal costs such as loss of productivity and workforce; whereas in 2018, no more than 2.8 % of total health expenditure in the EU was spent on prevention, whereas the costs of treating NCDs remains high5 ; _________________ 5 European Commission, ‘Healthier together – EU non-communicable diseases initiative’, p. 15, June 2022.
Amendment 86 #
Motion for a resolution
Recital D
Recital D
D. whereas the increasing burden of NCDs on individuals and societies and the health needs of ageing populations, 40% of which live with multimorbidity1a, represent challenges to the healthcare systems of the Member States; _________________ 1a Chowdhury S.R., Chandra Das D., Sunna T.C., Beyene J., Hossain A. Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta- analysis (2023) eClinicalMedicine, 57, art. no. 101860
Amendment 89 #
Motion for a resolution
Recital D
Recital D
D. whereas the increasing burden of NCDs affecting individuals and societies and the health needs of ageing populations represent challenges to the health systems of the Member States;
Amendment 96 #
Motion for a resolution
Recital D a (new)
Recital D a (new)
Da. whereas NCDs such as type 2 diabetes increasingly affect children; whereas many people living with NCDs such as diabetes are often diagnosed too late and many people already show signs of complications; 1a _________________ 1a https://link.springer.com/article/10.1007/s 11892-014-0508-y Diabetes Research and Clinical Practice, Volume 183, 2022, 109118, ISSN 0168-8227 https://doi.org/10.1016/j.diabres.2021.109 118.
Amendment 100 #
Motion for a resolution
Recital D a (new)
Recital D a (new)
Amendment 104 #
Motion for a resolution
Recital E
Recital E
E. whereas most NCDs are impacted by four main preventable risk factors: tobacco use, unhealthy diet, lack of physical activity and harmful use of alcohol; whereas behavioural risk factors lead to biological risk factors, the most common being overweight and obesity, high blood pressure, high blood glucose and high blood cholesterol6 ; whereas these risk factors often overlap, giving rise to severe complications and increased risk of developing other NCDs _________________ 6 World Health Organization, ‘Monitoring noncommunicable disease commitments in Europe 2021’, p. 13, 8 December 2021.
Amendment 131 #
Motion for a resolution
Recital F
Recital F
F. whereas most NCDs are impacted by environmental risk factors such as air pollutionindoor and outdoor air, water, soil and food pollution, noise and chemicals in the environment and the workplace, second- hand smoke, and some infectious agent;
Amendment 132 #
Motion for a resolution
Recital F
Recital F
F. whereas most NCDs are impacted by environmental risk factors such as air pollutionindoor and outdoor air pollution, chemical exposure as well as food, water and soil pollution; whereas most NCDs are impacted by socioeconomic inequalities;
Amendment 169 #
Motion for a resolution
Recital G b (new)
Recital G b (new)
Gb. whereas not all NCDs can be prevented as some factors are not modifiable such as age, family history, genetics, gender, auto-immunity (e.g. type 1 diabetes) and/or not known such as some neurological disorders;
Amendment 177 #
Motion for a resolution
Recital H
Recital H
H. whereas innovation with regard to development of technologies, medicines and healthcare practises is crucial to ensure the elimination or reduction of harm caused by preventable risk factors, early detection, integration of care, improved diseases management and therapeutic adherence, and new and better treatments for NCDs;
Amendment 180 #
Motion for a resolution
Recital H
Recital H
H. whereas innovation with regard to development of technologies, medicines and healthcare practises is crucial to ensure the elimination or reduction of harm caused by preventable risk factors, early detection, improved disease management, integration of care and new and better treatments for NCDs;
Amendment 187 #
Motion for a resolution
Recital H a (new)
Recital H a (new)
Ha. whereas approximately half of people living with diabetes are not achieving or maintaining optimal blood glucose targets1a, leading to an increased risk of diabetesrelated complications resulting in deterioration of well-being and other consequences including productivity loss and costs for society; _________________ 1a Blonde L, Aschner P, Bailey C, et al. Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Diabetes and Vascular Disease Research. 2017;14(3):172-183. doi:10.1177/1479164116679775
Amendment 189 #
Motion for a resolution
Recital H a (new)
Recital H a (new)
Ha. whereas people suffering from NCDs run a higher risk of being affected by communicable diseases such as COVID-19; whereas data shows that people suffering from NCD’s run a higher risk of complications and dying from COVID-19; 1a _________________ 1a https://health.ec.europa.eu/system/files/20 22-06/eu-ncd- initiative_publication_en_0.pdf page 57
Amendment 199 #
Motion for a resolution
Recital H b (new)
Recital H b (new)
Hb. whereas WHO has set a goal to reduce premature deaths from NCDs by 25% by 2025 and world leaders reaffirmed their commitment at the G20 Health Ministers meeting to achieving the UN’s Sustainable Development Goal (UNSDG) 3.4: to reduce premature deaths from NCDs by one-third by 2030; 1a _________________ 1a https://www.who.int/teams/noncommunic able-diseases/on-the-road-to-2025
Amendment 200 #
Motion for a resolution
Recital H b (new)
Recital H b (new)
Hb. whereas suboptimal therapeutic adherence and therapeutic inertia can lead to worse health outcomes and irreversible complications, increased mortality and higher costs;
Amendment 201 #
Motion for a resolution
Recital H c (new)
Recital H c (new)
Amendment 215 #
Motion for a resolution
Paragraph 1
Paragraph 1
1. Highlights that NCDs account for 90 % of all deaths in the EU8 , which leads to high levels of productivity loss and makes NCDs account for the largest share of countries’ healthcare expenditures; stresses that it is important to reduce the prevalence of NCDs and believes that enhanced health promotion and disease prevention can reduce the prevalence of NCDs by 70 %9 in conjunction with investment in health innovation and technologies, early diagnosis and screening, and better disease management; _________________ 8 European Commission, ‘Non- communicable diseases : overview’. 9 European Commission, ‘The EU ‘Healthier Together’ Non-Communicable Diseases Initiative’, 2022
Amendment 220 #
Motion for a resolution
Paragraph 1 a (new)
Paragraph 1 a (new)
Amendment 222 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Welcomes the Healthier together – EU non-communicable diseases (NCD) initiative, Europe’s Beating Cancer Plan, EU4Health work programme and the Commission Communication entitled ‘A comprehensive approach to mental health’; calls on the Commission to strengthen the ‘Healthier together – EU NCD’ initiative by introducing a holistic EU strategy on NCDs complemented by tailored action plans for specific NCDs; welcomes national plans and actions already taken against NCDs by, and in particular for highly prevalent diseases with high mortality and morbidity rates; with a view to not only revert the rising number of people living with NCDs but also to improve quality of life and well-being of people affected by NCDs; welcomes national plans and actions already taken against NCDs by Member States and calls on the European Commission to facilitate knowledge sharing and the scale up of good practices introduced by existing national plans across other Member States;
Amendment 233 #
Motion for a resolution
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Calls on the Member States to develop, implement and monitor national NCD plans and strategies, in particular for the most prevalent diseases with high mortality and morbidity rates, with comparable milestones and targets, including a risk-reduction and screening/early action component to target, among other things, the socio- economic determinants of health, the promotion of health-enabling environments and health and digital literacy, education and awareness rising aimed at both the population at large and at-risk groups in particular, and which is designed to reduce inequalities and optimise healthcare resources; Stresses that the national NCD plans should not only aim at reverting the rising number of people living with NCDs, but also at improving the quality of life and well- being of people affected by NCDs;
Amendment 246 #
Motion for a resolution
Paragraph 3 a (new)
Paragraph 3 a (new)
3a. Strongly believes that comprehensive preventive actions against non-communicable diseases, through measures supporting the elimination or reduction of harm caused by modifiable risk factors, should be implemented across all relevant European policies and funding programmes; calls on the Commission and the Member States to integrate public awareness-raising campaigns about non-communicable diseases prevention into all relevant policies; strongly believes that preventive actions should be evidence-based; therefore, calls on the Commission and Member States to increase the funding for scientific research into the causes of non- communicable diseases and the efficiency and implementation of preventive measures;
Amendment 248 #
Motion for a resolution
Paragraph 3 b (new)
Paragraph 3 b (new)
3b. Calls on the Commission and Member States to design and implement effective prevention measures at national and EU level, which are based on independent scientific expertise, best practices and lessons learned, and clinical guidance;
Amendment 249 #
Motion for a resolution
Paragraph 3 c (new)
Paragraph 3 c (new)
3c. Deplores the significant health inequalities and inequities in the EU in non-communicable diseases prevention; insists on the need to identify, as well as to pay special attention to, vulnerable, marginalised, socially excluded populations and people living in remote areas (such as in rural, isolated or outermost regions far from medical centres), in order to ensure their access to prevention services; considers in this regard that prevention measures also need to be framed in the context of social justice, entailing the need for systemic changes through population-wide public policies beyond changes in individual behaviour;
Amendment 250 #
Motion for a resolution
Paragraph 3 d (new)
Paragraph 3 d (new)
3d. Stresses the importance of viewing NCDs from a position that acknowledges that human, animal and environmental health are intrinsically linked and that therefore all actions to combat NCDs should be firmly rooted in the One Health approach;
Amendment 287 #
Motion for a resolution
Paragraph 5 – introductory part
Paragraph 5 – introductory part
5. Supports Europe’s Beating Cancer Plan to achieve a Tobacco-Free Generation and support the Commission’s proposals to review the Tobacco Products Directive11 and the Tobacco Taxation Directive12 and the proposal to update the Council recommendation of 30 November 2009 on smoke-free environments13 ; calls for a full implementation of the WHO Framework Convention on Tobacco Control; calls on the Commission and the Member States to: _________________ 11 Directive 2014/40/EU of the European Parliament and of the Council of 3 April 2014 on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco and related products, OJ L 127, 29.4.2014, p. 1. 12 Council Directive 2011/64/EU of 21 June 2011 on the structure and rates of excise duty applied to manufactured tobacco, OJ L 176, 5.7.2011, p. 24. 13 OJ C 296, 5.12.2009, p. 4.
Amendment 289 #
Motion for a resolution
Paragraph 5 – introductory part
Paragraph 5 – introductory part
5. Strongly supports the Commission’s proposals to review the Tobacco Products Directive11 and the Tobacco Taxation Directive12 and the proposal to update the Council recommendation of 30 November 2009 on smoke-free environments13 ; calls for a full implementation of the WHO Framework Convention on Tobacco Control; calls on the Commission and the Member States to: _________________ 11 Directive 2014/40/EU of the European Parliament and of the Council of 3 April 2014 on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco and related products, OJ L 127, 29.4.2014, p. 1. 12 Council Directive 2011/64/EU of 21 June 2011 on the structure and rates of excise duty applied to manufactured tobacco, OJ L 176, 5.7.2011, p. 24. 13 OJ C 296, 5.12.2009, p. 4.goal of a ‘tobacco-free generation’, as set out in the Europe’s Beating Cancer Plan, whose aim is for less than 5% of the population to use tobacco by 2040, compared to around 25% today; Supports the Commission’s proposals to review the Tobacco Products Directive and the Tobacco Taxation Directive, to introduce the following:
Amendment 291 #
Motion for a resolution
Paragraph 5 – point a
Paragraph 5 – point a
a. implement measures to helpCalls on the Member States and the Commission to fund programmes that promote smoking cessation, implement measures to support tobacco cessation to tobacco users quit;
Amendment 317 #
Motion for a resolution
Paragraph 5 – point b a (new)
Paragraph 5 – point b a (new)
ba. an increase and an upward convergence in minimum excise duties for all tobacco products and their final market price, which would improve prevention by reducing tobacco uptake and use, notably among current smokers, and prevent young people from starting smoking;
Amendment 320 #
Motion for a resolution
Paragraph 5 – point b b (new)
Paragraph 5 – point b b (new)
bb. a requirement for standardised plain packaging and the obligation to include health warnings on 80% of the front and back of tobacco product packaging, including pictorial warnings;
Amendment 325 #
Motion for a resolution
Paragraph 5 – point b c (new)
Paragraph 5 – point b c (new)
bc. the strict enforcement of the ban on characterising flavours in tobacco products to reduce the appeal of these products to smokers, non-smokers, and young people;
Amendment 337 #
Motion for a resolution
Paragraph 5 a (new)
Paragraph 5 a (new)
5a. Calls for the full implementation by Member States of the obligation under the Single Use Plastics Directive 2019/904 as regards filters in tobacco products containing plastics to address environmental and health concerns related to these filters,
Amendment 339 #
Motion for a resolution
Paragraph 5 b (new)
Paragraph 5 b (new)
Amendment 340 #
Motion for a resolution
Paragraph 5 c (new)
Paragraph 5 c (new)
5c. Supports the Commission’s proposal to update the Council recommendation of 30 November 2009 on smoke-free environments1a to extend its coverage to emerging products, such as e- cigarettes and heated tobacco products, and to extend smoke-free environments to include outdoor spaces; _________________ 1a OJ C 296, 5.12.2009, p. 4.
Amendment 345 #
Motion for a resolution
Paragraph 6
Paragraph 6
6. Highlights that one in ten deaths in the WHO Europe region results from alcohol use, or about 1 million deaths every year; Acknowledges that the harmful use of alcohol is a risk factor for multiple NCDs and underlines that the lower the amount of alcohol consumed, the lower the risk is of developing NCDs14 ; _________________ 14 Global burden of disease 2016 Alcohol Collaborators, ‘Alcohol use and burden for 195 countries and territories,1990–2016: a systematic analysis for the Global Burden of Disease Study 2016’, 23 August 2018.
Amendment 354 #
Motion for a resolution
Paragraph 7 – introductory part
Paragraph 7 – introductory part
7. Welcomes the Commission’'s objective tof achieving a 10 %e a reduction in harmful alcohol consumptionof at least 10% in the harmful use of alcohol by 2025; calls on the Commission and the Member States to:
Amendment 386 #
8. Notes that an unhealthy diet is one of the major risk factors for NCDs, including cardiovascular diseases, cancer, diabetes and other conditions linked to obesity15 ; emphasises the role of a healthy diet in preventing and limiting the incidence and the recurrence of non- communicable diseases, and stresses that individual risks can be reduced by an increased consumption of sustainably- produced plants and plant-based foods, such as fresh fruits and vegetables, whole grains and legumes; emphasises, furthermore, the need to address the overconsumption of meat and ultra- processed products, and products high in sugars, salt and fats; acknowledges that obesity is considered a risk factor for several NCDs; calls on the Commission and the Member States to: _________________ 15 World Health Organization Regional Office for the Eastern Mediterranean, ‘Noncommunicable diseases’.
Amendment 396 #
Motion for a resolution
Paragraph 8 – introductory part
Paragraph 8 – introductory part
8. Notes that an unhealthy diet is one of the major risk factors for NCDs, including cardiovascular diseases, cancer, diabetes, oral diseases and other conditions linked to obesity15 ; acknowledges that obesity is considered a risk factor for several NCDs; calls on the Commission and the Member States to: _________________ 15 World Health Organization Regional Office for the Eastern Mediterranean, ‘Noncommunicable diseases’.
Amendment 423 #
Motion for a resolution
Paragraph 8 – point b
Paragraph 8 – point b
b. pPropose a New EU Action Plan for childhood obesity; calls on the Member States to actively fight against obesity by making available healthy dietary choices and the practices of sports, not only by educating and encouraging citizens to make the right choices, but also by including integral programmes in primary healthcare that help patients suffering from obesity to lose weight in a healthy way; calls on the Commission and Member States to support research and innovation related to obesity aiming to describe the influence of genetic factors, the human microbiota or psychological status, among others, on body weight, and to explore the most effective interventions;
Amendment 454 #
Motion for a resolution
Paragraph 8 a (new)
Paragraph 8 a (new)
8a. Welcomes the Commission’s intention to tackle the presence of carcinogenic contaminants in food; urges the Commission to swiftly come forward with regulatory proposals;
Amendment 456 #
Motion for a resolution
Paragraph 8 b (new)
Paragraph 8 b (new)
8b. Calls on the Commission to heed Parliament’s various calls in its resolution of 16 January 2019 to improve the Union’s authorisation procedure for pesticides;
Amendment 470 #
Motion for a resolution
Paragraph 10
Paragraph 10
10. Considers the European Green Deal to be instrumental in preventing NCDs in the EUnion by reducing of air, food, water and soil pollution and chemical exposure; calls on the Commission to ensure that the common agricultural policy helps farmers to reduce the use of pesticides; encourages the research into, the use and the development of medicines that are safer for the environment, and encourages the implementation of efficient waste removal mechanisms that avoid polluting the environment, in line with the objectives of the Pharmaceutical Strategy for Europe; highlights that prevention of chronic respiratory diseases besides tobacco cessation also includes the prevention of exposure to dust and other indoor pollutants;
Amendment 498 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Stresses that some per- and polyfluorinated alkyl substances (PFAS) can lead to health problems such as obesity, diabetes 1a and cancer16 ; calls on the Commission to implement the PFAS restriction proposal submitted to European Chemicals Agency on 13 January 202317 ; _________________ 1a https://www.clinicaltrialsarena.com/comm ent/high-exposure-pfas-diabetes-women/ 16 European Environment Agency, ‘What are PFAS and how are they dangerous for my health?’. 17 European Chemicals Agency, ‘ECHA publishes PFAS restriction proposal’, 2023.
Amendment 499 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Stresses that per- and polyfluorinated alkyl substances (PFAS) can lead to health problems such as diabetes1a, obesity and cancer16 ; calls on the Commission to implement the PFAS restriction proposal submitted to European Chemicals Agency on 13 January 202317 ; _________________ 1a Park, S.K., Wang, X., Ding, N. et al. Per- and polyfluoroalkyl substances and incident diabetes in midlife women: the Study of Women’s Health Across the Nation (SWAN). Diabetologia 65, 1157– 1168 (2022). https://doi.org/10.1007/s00125-022- 05695-5 16 European Environment Agency, ‘What are PFAS and how are they dangerous for my health?’. 17 European Chemicals Agency, ‘ECHA publishes PFAS restriction proposal’, 2023.
Amendment 508 #
Motion for a resolution
Paragraph 13
Paragraph 13
13. RDeeply regrets the slow implementation of the Chemicals Strategy for Sustainability, and, in particular, expects thereiterates its call for a revision of REACH Regulation18 to be revised in order to be able to identify all substances of concern manufactured or imported in the EU; calls on the Commission to adopt effective guidance and legislation to reduce citizens’ exposure to carcinogenic substances; Fully supports the Commission’s proposal to amend the Regulation on the classification, labelling and packaging of chemicals (Regulation (EC) No 1272/2008) to introduce new hazard classes on, inter alia, EDs, including suspected EDs, and to update the information requirements in all relevant legislation to allow their identification; _________________ 18 Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), OJ L 396, 30.12.2006, p. 1.
Amendment 516 #
Motion for a resolution
Paragraph 13 a (new)
Paragraph 13 a (new)
13a. Recalls that the Commission’s Communication ‘Chemicals strategy for sustainability towards a toxic-free environment’ highlighted the need to protect workers from those substances; calls therefore on the Commission to consider extending the scope of Directive 2004/37/EC to endocrine disruptors;
Amendment 521 #
Motion for a resolution
Paragraph 13 b (new)
Paragraph 13 b (new)
Amendment 532 #
Motion for a resolution
Paragraph 14
Paragraph 14
14. Encourages the Commission and the Member States to achieve the UN Sustainable Development Goals that target communicable diseases in order to promote the prevention of NCDs such as cancer related to infectious diseases; welcomes vaccination programmes in this regard such as in the fight against human papillomavirus transmission; stresses the need for coordinated actions targeting carcinogenic viruses, such as HPV and the hepatitis B virus (HBV), in order to prevent their transmission; calls for more harmonisation of HPV and HBV vaccination within Member States’ national programmes, while ensuring the provision of information about vaccination and promoting equal access for vulnerable and at-risk adult groups; encourages the regular monitoring of current HPV and HBV vaccination at EU level using a tracking system similar to the COVID-19 vaccine tracker developed by the European Centre for Disease Prevention and Control (ECDC), that will also encourage Member States to adopt best practice and maintain momentum; supports further research on vaccine and innovative treatment options development against other viruses such as the hepatitis C virus and the human immunodeficiency virus (HIV); considers that in the meantime therapeutic solutions should be used massively to reach the WHO’s goal of eradicating hepatitis C by 2030, and calls on the Commission to use financial resources under the Recovery and Resilience Fund to reach these targets by funding screening efforts; further considers that greater political commitment and strong partnership and collaboration between authorities and all concerned actors is needed to reach the WHO's goal of ending the HIV/AIDS epidemic by 2030, including in Europe, and calls on the Commission and Member States to step up their support to ensure that all, including vulnerable communities more at risk, can be tested, diagnosed and have rapid access and are retained to the best care innovative options; also calls on the Commission and Member States to invest in and support high-impact innovative combination prevention approaches as a key additional tool to end the HIV epidemic in Europe; calls for cooperation with Member States and international organisations to combat the impact of misinformation on vaccination and to address vaccine hesitancy; calls for the EU4Health and other EU funding streams to be used for this purpose, including for supporting awareness-raising efforts for citizens, education providers and healthcare professionals, as well as for support to behavioural research under the Horizon Europe programme; recommends a strengthened application of the EU’s Code of Practice on Disinformation particularly with regard to vaccine misinformation;
Amendment 550 #
Motion for a resolution
Paragraph 14 a (new)
Paragraph 14 a (new)
14a. Calls for the implementation of prevention programmes to be inclusive by involving regions and municipalities, citizens, the social partners, civil society and patient organisations at all steps of the decision-making process,
Amendment 552 #
Motion for a resolution
Paragraph 14 b (new)
Paragraph 14 b (new)
14b. Encourages the Commission and the Member States to further promote health literacy on NCDs’ risks and determinants as well as digital literacy that is linked to it, to develop educational tools for prevention, and to support the creation of e-learning platforms and applications; calls for particular attention be paid to disadvantaged, vulnerable, socially excluded and marginalised people, and underlines that specific awareness-raising campaigns for groups with particular health literacy needs are essential;
Amendment 562 #
Motion for a resolution
Paragraph 15
Paragraph 15
15. Highlights the importance of identifying people with a high risk of developing NCDs and diagnosing people as early as possible for example through the implementation of health checks and early detection programmes in order to improve disease management, prevent complications and save downstream costs for healthcare systems;
Amendment 574 #
Motion for a resolution
Paragraph 15 a (new)
Paragraph 15 a (new)
Amendment 576 #
Motion for a resolution
Paragraph 15 b (new)
Paragraph 15 b (new)
15b. Emphasises that NCD prevention and management, i.a. through improved therapeutic adherence and personalised care, can help lighten the burden of NCDs on healthcare systems and strengthen their resilience in the face of health crises and unexpected shocks;
Amendment 580 #
Motion for a resolution
Paragraph 16
Paragraph 16
16. Encourages Member States to reduce undiagnosed NCDs by introducing joint targeted health checks for high-risk individuals addressing the main shared metabolic risk factors, ensuring such as high blood pressure, high blood glucose, high BMI and high LDL cholesterol as well incentivising self-tests such as stool collection to detect colorectal cancer and self-test for cervical cancer, ensuring timely access to quality care and support NCD patients’ self- management;
Amendment 581 #
Motion for a resolution
Paragraph 16
Paragraph 16
16. Encourages Member States to reduce undiagnosed NCDs by introducing targeted health checks ofor high-risk individuals addressing the main shared metabolic risk factors, ensuring timely access to high-quality care and support NCDs patients’ self- management; calls on the Commission and the Member States to support the development and the use of novel tools to diagnose NCDs in at-risk populations;
Amendment 590 #
Motion for a resolution
Paragraph 16 a (new)
Paragraph 16 a (new)
16a. Highlights the importance of early intervention in the case of mental health problems; stresses that daycares, schools and workplaces can play an important role in recognising mental health problems at early stages and that timely support can be provided; 1a _________________ 1a https://health.ec.europa.eu/system/files/20 23-06/com_2023_298_1_act_en.pdf
Amendment 593 #
17. Notes that some NCDs are closely linked such as diabetes and cardiovascular diseases and that the interlinks between these conditions exacerbate their respective morbidity and mortality; further notes that important synergies can be achieved by improving diagnosis and integrated care19 ; _________________ 19 European Commission, ‘Healthier together – EU non-communicable diseases initiative’, p. 30, June 2022.
Amendment 607 #
Motion for a resolution
Paragraph 18 b (new)
Paragraph 18 b (new)
18b. Regrets the disparities in terms of access to high-quality healthcare services among Member States, and also among different regions within Member States, and asks the Commission to address those disparities through the appropriate legislative measures in order to ensure equal rights in the EU;
Amendment 610 #
Motion for a resolution
Paragraph 18 c (new)
Paragraph 18 c (new)
18c. Emphasises the need to deploy person-centred, continued, and fully integrated care across the entire chronic diseases care pathway and to strengthen community and priority care, with a focus on chronic diseases requiring access to care across specialties and care levels; calls on the Member States to review and as appropriate advance their national models of care to this end, with the support of the Commission through the Recovery and Resilience Facility, guided by the European Semester process;
Amendment 611 #
Motion for a resolution
Paragraph 18 d (new)
Paragraph 18 d (new)
18d. Believes that the high interconnection between some NCDs, such as diabetes, cardiovascular diseases, renal diseases, obesity and mental health can exacerbate their respective morbidity and mortality, and therefore requires a holistic and integrated approach, complemented by disease specific priorities for action; notes the potential benefits of a comprehensive strategy, taking into account disease progression over the life course; calls on the Commission to develop an NCD prevention and management blueprint, complemented by disease-specific programmes including clear targets, benchmark indicators and a monitoring framework;
Amendment 615 #
Motion for a resolution
Paragraph 18
Paragraph 18
18. Stresses that nurses, doctors, general practitioners and other primary and proximity care professionals as well as patient organisations and the third sector at large have a significant role in referring patients for diagnostic tests and treating NCDs; encouragescalls on the Member States to ensure continued patient access to primary and secondary care, and to offer training to healthcare professionals toso that they can better identify highand support at-risk individuals and, treat NCDs according to the latest evidence-based studies and address i.a. therapeutic inertia and adherence;
Amendment 620 #
Motion for a resolution
Paragraph 18
Paragraph 18
18. Stresses that nurses, doctors, general practitioners. dental health professionals, dietitians and nutritionists and other primary healthcare professionals have a significant role in referring patients for diagnostic tests and treating NCDs; encourages the Member States to offer training to healthcare professionals to better identify high-risk individuals, prevent and treat NCDs;
Amendment 627 #
Motion for a resolution
Paragraph 18
Paragraph 18
18. Stresses that nurses, doctors, general practitioners and other primary care professionals have a significant role in referring patients for diagnostic tests and treating NCDs; encourages the Member States to offer training to healthcare professionals to better identify highat-risk individuals and treat NCDs;
Amendment 635 #
Motion for a resolution
Paragraph 18 a (new)
Paragraph 18 a (new)
18a. Highlights that the pandemic exacerbated existing structural issues in the public health and care sectors, in particular workforce shortages;
Amendment 654 #
Motion for a resolution
Paragraph 19
Paragraph 19
19. Believes that every patient is different and no NCD is the same; calls for NCDs to be prevented and treated as effectively as possible, with a personalised evidence-based and integrated approach tailored to the disease and the patient, and the diseaseensuring the latter's meaningful information and engagement;
Amendment 660 #
Motion for a resolution
Paragraph 19 a (new)
Paragraph 19 a (new)
19a. Notes that the Covid-19 pandemic has highlighted how serious health threats can put severe pressure on the capacities of healthcare systems, with a negative impact on the provision of healthcare for patients with non- communicable diseases, such as the continuity of healthcare, delay of or interruption to treatment for patients and people with mental health issues1a; underlines that the impact of serious cross-border threats to health may thus pose further challenges in ensuring a high level of human health protection; stresses the need for Member States to anticipate and to monitor the impact of public health emergencies on the provision of healthcare services for other diseases and conditions, while respecting the responsibilities of Member States for the definition of their health policy and for the organisation and delivery of health services and medical care; _________________ 1a Invisible numbers: the true extent of NCDs and what to do about them. Geneva: World Health Organization; 2022.
Amendment 674 #
Motion for a resolution
Paragraph 19 a (new)
Paragraph 19 a (new)
19a. Highlights the importance of addressing social determinants, health literacy, and digital literacy to reduce the overall burden of NCDs;
Amendment 677 #
Motion for a resolution
Paragraph 19 b (new)
Paragraph 19 b (new)
19b. Calls for the adoption of an EU strategy to anticipate and monitor the impacts of serious health threats on people affected by communicable and non-communicable diseases/other diseases or conditions; proposes to constitute a European NCD specialists emergency reserve composed of voluntary NCDs experts trained and ready to be deployed to ensure care to people living with NCDs in any Member State or neighboring country in crisis time;
Amendment 687 #
Motion for a resolution
Paragraph 19 c (new)
Paragraph 19 c (new)
Amendment 693 #
Motion for a resolution
Paragraph 19 d (new)
Paragraph 19 d (new)
19d. Asks for enhanced communication between health professionals, patients, survivors, caregivers, parents and public authorities regarding the effectiveness and safety of health interventions, in particular NCDs’ diagnosis and treatment, and for increased awareness campaigns for prevention in times of crisis;
Amendment 697 #
Motion for a resolution
Paragraph 19 e (new)
Paragraph 19 e (new)
19e. Calls on the Member States and relevant authorities to recognise the pivotal role of informal carers, integrate them into health and care teams and empower them with the possibility of making informed choices regarding available supportive measures with the support of healthcare professionals; recognises that the COVID-19 pandemic has exacerbated the crucial role of informal carers, who provide most of the daily care for NCDs patients and who face a clear lack of practical and policy support, including as regards social rights, training, psychological help, information and recognition; points to the high percentage of informal carers among the EU population and to the disparities regarding the way in which they are supported and how their rights are recognised across Member States; calls on the Commission to consider the formalisation of informal care, which would ensure the recognition of a certain minimum standard of rights, especially for those who are providing long-term care;
Amendment 705 #
Motion for a resolution
Paragraph 20
Paragraph 20
20. Recalls that patient empowerment and health literacy areis crucial for an EUuropean NCDs strategy and that treatment and care should be patient- centred; encourages the promotion of well- informed patients who are actively involved in their own treatment and calls for the therapeutic training of caregivers and patients and their empowerment in the care programmes; calls for participatory decision-making, with personalised and understandable evidence-based information to be provided to patients, calls for the support of such initiatives and actions to empower cancer patients through EU funding, especially the EU4Health Programme;
Amendment 716 #
Motion for a resolution
Paragraph 21
Paragraph 21
21. Notes the need to focus on the quality of life of NCD patients whose illnesses cannot be cured but may be stabilised for a number of years; emphasises the importance of specific EU recommendations to improve the quality of life of patients including by integrating comprehensive supportive care into care, starting with the diagnosis and continuing over the course of the disease and by granting access to specialised support centres;
Amendment 721 #
Motion for a resolution
Paragraph 21 a (new)
Paragraph 21 a (new)
21a. Stresses that NCDs’ patients should not suffer a ‘double punishment’ in their daily lives; calls for the adoption of an anti-discrimination directive, as well as for the fair and equal implementation of directives on financial services, such as the Consumer Credit Directive, without any discrimination against NCDs’ patients and survivors;
Amendment 723 #
Motion for a resolution
Paragraph 21 a (new)
Paragraph 21 a (new)
Amendment 724 #
Motion for a resolution
Paragraph 21 b (new)
Paragraph 21 b (new)
21b. Encourages the Member States to take into account the frequent exhaustion of the families and relatives of NCDs patients and to provide them with psychological and socioeconomic assistance, especially to the most vulnerable, and rest periods in the workplace, throughout the course of the disease, as well as with bereavement support; encourages, furthermore, the development of integrated, adequate and accessible support schemes for NCDs’ patients and their families, that take health, community and social services into account;
Amendment 726 #
Motion for a resolution
Paragraph 21 c (new)
Paragraph 21 c (new)
21c. Acknowledges the central role of independent patients’ and carers’ associations in relation to patient advocacy and accompaniment, services provided to NCDs’ patients and caregivers, dissemination of health literacy, awareness raising and ongoing support both at EU and national level; calls on the Commission and the Member States to take into account the formal participation of these associations, as well as their requests and recommendations, when formulating NCDs’ policies and legislation, and to provide them with public support in the form of both operating grants and project-related grants in order to guarantee their independence from private funding; calls on the Commission to set clear criteria according to which public financial support can be awarded.
Amendment 731 #
Motion for a resolution
Paragraph 22
Paragraph 22
22. Welcomes the pharmaceutical package and calls for the strengthening of the European medicines market to ensure equal access to medicines and alleviate medicine shortages,, including innovations and personalised medicines, alleviate medicine shortages, overcome the problem of high prices for innovative technologies and treatments, encourage the use of generic and biosimilar medicine and reduce barriers to cross- border business, while strengthening incentives for investments in innovation; underlines that data protection and intellectual property rights are crucial to ensure competitiveness in the EU by incentivising innovators to develop new products and further ongoing research efforts;
Amendment 739 #
Motion for a resolution
Paragraph 22 a (new)
Paragraph 22 a (new)
22a. Welcomes the creation of the IPCEI on Health to support innovation and to improve quality and access to care for European patients; considers the Health IPCEI should facilitate the development of innovative and greener technologies and production processes for drug manufacturing, of gene and cell therapies and innovation in strategic treatments;
Amendment 745 #
Motion for a resolution
Paragraph 22 b (new)
Paragraph 22 b (new)
22b. Considers that the future European Sovereignty Fund could help restore EU's strategic autonomy on medical products;
Amendment 747 #
22c. Calls for the adoption of a Critical Medicines Act to support the European green, digital manufacturing of critical medicines, APIs and intermediate ingredients to diversify the EU pharmaceutical supply chains and to secure the strategic autonomy of critical medicines, in parallel of the review of the European pharmaceutical legislation;
Amendment 748 #
Motion for a resolution
Paragraph 22 d (new)
Paragraph 22 d (new)
22d. Notes that NCDs’ patients are frequently affected by medicine shortages and that severe disruptions in the supply of their treatments are highly detrimental to them, their carers and their families; calls on the Commission and the Member States to work together to prevent and manage shortages of all medicines and medical products and of NCDs medicines in particular, including shortages of inexpensive essential NCDs medicines; supports the development of a common basket of NCDs’ drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment, based on transparently and appropriately defined patient needs;
Amendment 749 #
Motion for a resolution
Paragraph 22 e (new)
Paragraph 22 e (new)
22e. Calls for the reinforcement and diversification of the supply chain of medicines within the EU, close monitoring of supply tensions and shortages, and the creation of a strategic stockpile of critical medicines, active ingredients and raw materials, particularly where the number of suppliers is limited; stresses the importance of the role of sustainable procurement practices in preventing medicine shortages;
Amendment 750 #
Motion for a resolution
Paragraph 22 f (new)
Paragraph 22 f (new)
22f. Urges the Commission to submit a proposal for the revision of Council Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products in order to ensure effective scrutiny and greater transparency of the procedures used to determine the price of and reimbursement amount for medicines, particularly cancer medicines, in all Member States;
Amendment 751 #
22g. Insists on the need to ensure equal access to affordable drugs to every European citizen; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration;
Amendment 752 #
Motion for a resolution
Paragraph 22 h (new)
Paragraph 22 h (new)
22h. Strongly advocates the extension of joint procurement procedures for NCDs medicines to counter shortages and improve affordability and access to those treatments at EU level; recalls that Joint Procurement Agreements should be carried out in a transparent, timely and effective way; underlines, in this respect, that clear and transparent stages for the process, scope, tender, specifications, timelines and formalities should be defined;
Amendment 753 #
Motion for a resolution
Paragraph 22 i (new)
Paragraph 22 i (new)
Amendment 770 #
Motion for a resolution
Paragraph 24
Paragraph 24
24. Calls on the Commission to strengthen support and investment in the development of, and access to, new innovative medical devices, and to support the digitalisation of national health services; believes that new technologies and digitalisation can lead to new and better treatments formanagement and treatments for NCDs as well as improved quality of life for people living with NCDs;
Amendment 790 #
Motion for a resolution
Paragraph 25
Paragraph 25
25. Believes that improving knowledge and sharing of evidence-based best practices among Member States is needed to accelerate effective prevention measures and innovative practices, and improve management of NCDs, quality of care and health outcomes;
Amendment 815 #
Motion for a resolution
Paragraph 27
Paragraph 27
27. Calls on the Commission to create a European NCD Health Knowledge Centre to improve data collection and research on NCDresearch in NCDs and collection of comparable, robust data on NCDs at EU level, to outline the cost effectiveness of prevention strategies and stimulate investment in the area – ensuring synergies and integration with European Health Data Space plans; stresses the need for further research in NCD co-morbidities and management;
Amendment 824 #
Motion for a resolution
Paragraph 27 a (new)
Paragraph 27 a (new)
27a. Stresses that good quality data are important to support development of evidence-based and targeted policies for improved health; notes that correlating health data with environmental, social and economic data and strengthening elements of existing health monitoring systems such as European Health Data Space is important in this regard;
Amendment 827 #
Motion for a resolution
Paragraph 27 a (new)
Paragraph 27 a (new)
27a. recognises the potential of interoperable and flexible diabetes data registries in improving quality of care and health outcomes; calls on Member States to put in place NCD-specific data registries;
Amendment 830 #
Motion for a resolution
Paragraph 28
Paragraph 28
28. Welcomes tThe Commission Expert Group on Public Health and the sub-group on NCDnon- communicable diseases; calls on the Commission to establish a European expertise network for prevention and control of NCD co- morbidities and complications, based on the model of the European Reference Networks (ERNs);